Skip to main content
. 2023 Nov 17;4(2):20210146. doi: 10.1002/EXP.20210146

FIGURE 2.

FIGURE 2

Schematic illustration of mRNA structural modification, adjuvant adding, nucleoside modification, and codon optimization for improved mRNA‐based cancer immunotherapy. A Schematic illustration of the preparation and application of ChriST mRNA in DCs‐targeted cancer immunotherapy. Reproduced with permission.[ 39 ] Copyright 2020, Elsevier. B The expression levels of fLuc mRNA in vivo with modified and unmodified mRNA and other treatments. C Adjuvant α‐GalCer and nucleoside modification in promoting the stability of mRNA and improving the antigen‐presenting ability of DCs. Reproduced with permission.[ 45 ] Copyright 2019, American Chemical Society. D Schematic illustration of codon optimization in prolonging the transcript half‐life of mRNA. E Box plot of mRNA stability with optimal codons percent. Reproduced with permission.[ 46 ] Copyright 2015, Elsevier.